➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Express Scripts
Baxter
Johnson and Johnson
Medtronic

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,659,282

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,659,282
Title:Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
Abstract:Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Inventor(s): Yakatan; Gerald (Del Mar, CA), Berg; James (San Diego, CA), Pope; Laura E. (Carlsbad, CA), Smith; Richard A. (La Jolla, CA)
Assignee: Avanir Pharmaceuticals, Inc. (Aliso Viejo, CA)
Application Number:11/035,213
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,659,282
Patent Claims: 1. A method for treating pseudobulbar affect or emotional lability, the method comprising administering to a patient in need thereof dextromethorphan in combination with quinidine, wherein the amount of dextromethorphan administered comprises from about 20 mg/day to about 80 mg/day and wherein the amount of quinidine administered comprises from about 10 mg/day to less than about 30 mg/day with the proviso that the weight to weight ratio of dextromethorphan to quinidine is 1:0.5 or less.

2. The method of claim 1, wherein the pseudobulbar affect or emotional lability is caused by a neurodegenerative disease or condition or a brain injury.

3. The method of claim 1, wherein the dextromethorphan and the quinidine are administered as one combined dose per day.

4. The method of claim 1, wherein the dextromethorphan and the quinidine are administered as at least two combined doses per day.

5. The method of claim 1, wherein the amount of quinidine administered comprises from about 20 mg/day to about 30 mg/day.

6. The method of claim 1, wherein the amount of dextromethorphan administered comprises from about 20 mg/day to about 60 mg/day.

7. The method of claim 1, wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt.

8. The method of claim 1, wherein at least one of the quinidine and the dextromethorphan is in a form of a pharmaceutically acceptable salt selected from the group consisting of salts of free acids, inorganic salts, salts of sulfate, salts of hydrochloride, and salts of hydrobromide.

9. The method of claim 1, wherein about 20 mg quinidine sulfate is administered per day.

10. The method of claim 9, wherein about 60 mg dextromethorphan hydrobromide is administered per day.

11. The method of claim 1, wherein about 60 mg dextromethorphan hydrobromide is administered per day.

12. The method of claim 1 wherein the dextromethorphan and quinidine are administered in separate doses.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Mallinckrodt
McKinsey
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.